Filter By:

Reset
ACS and Interventional Cardiology Research

We have spent two decades focusing on how, when and where to best treat heart attacks, a form of acute coronary syndromes (ACS) – from assessing if early coronary intervention benefits high-risk patients, to evaluating anti-inflammatory and aldosterone-block drugs in ACS patients, and more. Landmark studies in the ACS program include COMPLETE, RIVAL, AND OASIS 4 (CURE).

Team Members in ACS and Interventional Cardiology

Shamir Mehta

Senior Scientist

Shamir Mehta
Senior Scientist

Shamir Mehta is a Senior Scientist with the Acute Coronary Syndrome and Interventional Cardiology research program at PHRI, a Professor of Medicine at McMaster University, and Director of the Interventional Cardiology program at Hamilton Health Sciences. His research focuses on the role and timing of invasive therapies in patients with acute ischemic heart disease, and the evaluation of novel antiplatelet and anticoagulant therapies in these patients.

He has led several large pragmatic randomized trials evaluating invasive interventional strategies in patients with acute coronary syndromes. He has also lead multinational randomized trials evaluating novel antiplatelet and anticoagulant therapies to improve outcomes in patients experiencing a heart attack.

Shamir Mehta has published 127 original research papers in several medical journals including The New England Journal of Medicine, The Lancet, JAMA, and Circulation. His success in research has earned him a coveted Canada’s Top 40 under 40TM award in 2004, and he has received a Canadian Institutes of Health Research New Investigator Career Award.

Sanjit Jolly

Scientist

Sanjit Jolly
Scientist

Sanjit Jolly is an interventional cardiologist at Hamilton Health Sciences and associate professor at McMaster University. He has formal training in clinical trials with a M.Sc. in Health Research Methodology from McMaster. He was the principal investigator of the RIVAL trial, a randomized trial of 7021 patients comparing radial and femoral access for coronary intervention. He is also the principal investigator trial of the ongoing TOTAL trial, an international randomized trial (N=10,700) of thrombectomy during primary PCI.

Madhu Natarajan

Scientist

Madhu Natarajan
Scientist

Madhu Natarajan is an interventional cardiologist and Principal Investigator for the Coronary Interventional Health Delivery and Knowledge Translational and Implementation programs at PHRI. He is a Professor at McMaster University, Director of Catheterization Laboratories at Hamilton Health Sciences, and Site Director for Cardiology at Hamilton General Hospital.

He has published more than 85 articles, is Chair of the STEMI-EMS Committee, Cardiac Care Network of Ontario, member of the Royal College Cardiology National Examination Board, and program lead for Regional STEMI network in LHIN-4 Ontario.

JD Schwalm

Scientist

JD Schwalm
Scientist

JD Schwalm is a Principal Investigator in the Knowledge Translation and Health Systems research program at PHRI, an Associate Professor, Department of Medicine (cardiology) at McMaster University, and an interventional cardiologist at Hamilton Health Sciences. He has published more than 50 peer-reviewed scientific papers and book chapters.

He completed medical school, internal medicine residency, and cardiology fellowship training at McMaster University, Ontario, followed by an interventional cardiology fellowship at McMaster and further training in that field at the University of Ottawa Heart Institute. He is a fellow of the Royal College of Physicians and Surgeons of Canada, with certification in internal medicine and cardiology.

Tej Sheth

Scientist

Tej Sheth
Scientist

Tej Sheth is a Scientist with the Perioperative and Surgery research program at PHRI, as well as a Principal Investigator in atherosclerosis imaging, an Associate Professor in the Department of Medicine at McMaster University, and a interventional cardiologist at Hamilton Health Sciences. His research interests include invasive and non-invasive coronary imaging modalities, including coronary angiography, optical coherence tomography, and CT coronary angiography. He is Director of the CT Angiographic Core Lab for the COMPASS CABG study and the COMPLETE trial at PHRI.

completed

OASIS 8 FUTURA

ACS and Interventional Cardiology

The objective of the OASIS 8 FUTURA study was to compare the safety of two...

completed

PCI-CURE

ACS and Interventional Cardiology

 Despite the use of aspirin, there is still a risk of ischaemic events after percutaneous...

completed

RADIATION PROTECTION

ACS and Interventional Cardiology

The objective of RADIAL PROTECTION was to assess the utility of using a novel radiation...

completed

RIVAL

ACS and Interventional Cardiology

The objective of the RIVAL study was to demonstrate the efficacy and safety of dabigatran...

completed

TIMACS

ACS and Interventional Cardiology

The objective of the TIMACS study was to compare relative efficacy, safety, and cost effectiveness...

completed

TOTAL

ACS and Interventional Cardiology

Two large trials, prior to the TOTAL study, had reported contradictory results at one year...

Back To Top